Search | Clinical Trials Finder

Conditions: Behcet's Disease, Churg-Strauss Syndrome, Vasculitis, Central Nervous System, Giant Cell Arteritis, Wegener Granulomatosis, Henoch-Schoenlein Purpura, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Fluid Loss, Symptom Complex, Triple, Emergencies
Interventions: Lactated Ringer Solution, Normal Saline 0.9% Infusion Solution Bag; Drug
Lead sponsor: Nicholas M Mohr; Other
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Uveitis
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 8 Years to 100 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: NOMID, DIRA, NLRC4-MAS, SAVI, CANDLE
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 99 Years
Enrollment: 3,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Wegener Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Polyarteritis Nodosa, Giant Cell Arteritis, Takayasu's Arteritis, Henoch-Schoenlein Purpura, Behcet's Disease, CNS Vasculitis
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE), Juvenile Dermatomyositis (JDM), Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI), Aicardi-Goutières Syndrome (AGS)
Interventions: Baricitinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Months and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Bethesda, Maryland • Philadelphia, Pennsylvania

Conditions: Behcet Syndrome
Interventions: Apremilast (CC-10004), Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Jacksonville, Florida • Boston, Massachusetts • New York, New York + 1 more

Conditions: Inherited Immune Deficiencies
Interventions: Campath 1H, Busulfan, Horse Anti-human Thymocyte Globulin (h-ATG), Total Body Irradiation (TBI), Sirolimus or equivalent based on response; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cryopyrin-Associated Periodic Syndrome
Interventions: ATI-450; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: San Diego, California • San Francisco, California

Conditions: Still's Disease, Adult-Onset, Systemic Inflammation, Arthritis, Autoinflammatory Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 1 Day to 100 Years
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2050
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hyper IgD Syndrome, Mevalonate Kinase Deficiency
Interventions: Not listed
Lead sponsor: Michigan Technological University; Other
Eligibility: 18 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: Houghton, Michigan • Omaha, Nebraska • Portland, Oregon

Conditions: Inflammation, Familial Mediterranean Fever, Still's Disease, Adult-Onset
Interventions: IL-1 Trap; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Muckle Wells Syndrome
Interventions: ACZ885, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 4 Years to 75 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 3
States / cities: San Francisco, California • Chicago, Illinois • Madison, Wisconsin

Conditions: Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain
Interventions: Dapansutrile, Placebo Tablet; Drug · Other
Lead sponsor: Olatec Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 25
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 21 more

Conditions: Familial Cold Autoinflammatory Syndrome
Interventions: DFV890; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: XIAP Deficiency, NLRC4-MAS
Interventions: Tadekinig alfa; Drug
Lead sponsor: AB2 Bio Ltd.; Industry
Eligibility: Not listed
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 8
States / cities: La Jolla, California • Gainsville, Florida • Atlanta, Georgia + 5 more

Conditions: Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
Interventions: Canakinumab (ACZ885); Drug
Lead sponsor: Novartis; Industry
Eligibility: 3 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Little Rock, Arkansas • San Francisco, California • Columbus, Georgia + 3 more

Conditions: NLRC4-MAS, XIAP Deficiency
Interventions: Tadekinig alfa, 0.9% sodium chloride; Drug · Other
Lead sponsor: AB2 Bio Ltd.; Industry
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 6
States / cities: La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 3 more

Conditions: Autoimmune Connective Tissue Disorder, Immune System Diseases
Interventions: Anakinra; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome, VEXAS, Vexas Syndrome
Interventions: Pacritinib; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Familial Mediterranean Fever
Interventions: colchicine sprinkle capsules; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cryopyrin-Associated Periodic Syndromes, Amyloidosis
Interventions: 124I AT-01; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM), Immune-mediated Necrotizing Myopathy (IMNM), Immune Thrombocytopenia (ITP)
Interventions: RAY121; Drug
Lead sponsor: Chugai Pharmaceutical; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Orange, California • Baltimore, Maryland • Lake Success, New York + 8 more

Conditions: Immunodeficiency, Hematopoietic Stem Cell Transplantation
Interventions: Allogeneic HSCT, Busulfan test dose, Mycophenolate mofetil (MMF), Tacrolimus, Busulfan, Total Body Irradiation (TBI), Fludarabine, Cyclophosphamide (CY), Post-Transplant Cyclophosphamide (PTCY); Procedure · Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Educational Needs of Patients With Systemic Vasculitis

Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation

Uveitis/Intraocular Inflammatory Disease Biobank (iBank)

Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)

Vasculitis Illness Perception (VIP) Study

Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes

A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease

Donor Stem Cell Transplantation for Congenital Immunodeficiencies

Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)

Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions

B7 Coreceptor Molecules in Hyper IgD Syndrome Form of Mevalonate Kinase Deficiency

Interleukin-1 Trap to Treat Autoinflammatory Diseases

Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome

Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension

Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

Anakinra for Behcet s Disease

Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients

Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome